References

149

REFERENCES

Aaberg TM: Management of anterior and posterior proliferative

vitreoretinopathy. Am J Ophthalmol 1988; 106: 519-532.

Abrams GW and Glazer LC: Proliferative vitreoretinopathy. In Freeman

WR (ed.): Practical atlas of retinal disease and therapy (second

addition), Lippincott-Raven, Philadelphia, USA, 1998, pp

303-323.

Adel SS: Minimal extraocular surgery in retinal detachment with

proliferative vitreoretinopathy. Bull Ophthalmol Soc Egypt 2001;

94 : 493 -7.

Akpek EK, Hasiripi H, Christen WG, and Kalayci D: A randomized trial

of low dose topical mitomycin C in the treatment of severe vernal

keratoconjunctivitis. Ophthalmology 2000; 107 : 263-7

Alexander RA, Hiscott P, McGalliard J and Grierson I: Oxylatan fibers

in proliferative vitreoretinopathy. Ger J Ophthalmol 1992; 1:

382-387.

Ali KG and Zaki I : Toxic effects of intravitreal 5-fluorouracil and

mitomycin C on rabbit eyes. Bull Ophthalmol Soc Egypt 1995; 88

: 839 – 44.

Alio JL and BenEzra D: Intraocular inflammation : is there any light at

the end of the tunnel ? Highlights of Ophthalmology 2002; 30

: 2 - 7.

Alvira G, Hartzer M and Blumenkranz M: Heparin : a possible new

aporoach to the treatment of proliferative vitreoretinopathy. In :

References

150

Proliferative vitreoretinopathy. Heimann K, Weidemann P (eds).

Heidelberg, Germany: Kaden Verlag, 1989 : 268 – 71.

Antoszyk AN and McCuen BW II: Vitreous surgery in proliferative

vitreoretinopathy. In : Duane's Ophthalmology (CD-Rom edition).

Tasman W, Jaeger EA (ed.). 530 Walnut Street Philadelphia, PA

19106 : Lippincott Williams and Wilkins publishers Inc., 2002;

Chapter 58.

Araiz JJ, Refojo MF and Arroyo M: Antiproliferative effect of retinoic

acid in intravitreal silicone oil in an animal model of proliferative

vitreoretinopathy. Invest Ophthalmol Vis Sci 1993; 34 : 522 – 30.

Asaria RHY, Kon CH and Bunce C : Silicone oil concentrates fibrogenic

growth factors in the retro – oil fluid. Br J Ophthalmol 2004; 88 :

1439 – 42.

Asaria RHY, Kon CH, Bunce C, Charteris DG, Wong D, Khaw PT and

Ayelward GW: Adjuvant 5-fluorouracil and heparin prevents

proliferative vitreoretinopathy. Ophthalmology 2001b; 108 :

1179- 83.

Asaria RHY, Kon CH, Bunce C, et al: How to predict proliferative

vitreoretinopathy- a prospective study. Ophthalmology 2001 a;

108: 1184-1186.

Ayelward GW: Proliferative vitreoretinopathy. In : Ophthalmology

(second edition). Yanoff M, Duker JS (eds) 11830 Westline

Industrial Drive, St Louis, Missouri 63146 : Mosby Inc., 2004 :

1002 – 6.

References

151

Ayelward GW: Retinal detachment: Proliferative vitreoretinopathy In

Yanoff M, Duker JS (eds.): Ophthalmology (1st ed.). Mosby,

section 8.42, London, UK, 1999, pp 1-6.

Azen SP, Scott IU and Flynn H.: Silicone oil in the repair of complex

retinal detachments : a prospective, observational, multicenter

study. Ophthalmology 1998; 105 : 1587 – 97.

Baird A and Klagsburn M: The fibroblast growth factor family – an

overview. Ann NY Acad Sci 1991; 638: xi-xii.

Barr CC, Stern W and Lai My for Silicon Study Group: Postoperative

intraocular pressure abnormalities in the silicone study. Silicone

Study report 4. Ophthalmology 1993; 100 : 1629 – 35.

Bassat IB, Desatnik H, Alhalel A, Treister G and Moissiev J: Reduced

rate of retinal detachment following silicone oil removal : Retina

2000; 20 : 597 – 603.

Baudouin C, Fredj-Reygrobellet D, Gordon W, et al: Immunohistologic

study of epiretinal membrane in proliferative vitreoretinopathy.

Am J ophthalmol 1990; 110:593-598.

Blankenship GW: Evaluation of a single intravitreal injection of 5-

fluorouracil in vitrectomy cases. Graefes Arch Clin Exp

Ophthalmol 1989; 227 : 565 -8.

Blumenkranz M, Hartzer MK and Hajek AS: Selection of therapeutic

agents for intraocular proliferative disease: II. Differing

antiproliferative activity of the fluoropyrimidines. Arch

Ophthalmol 1987; 105: 369-399.

References

152

Blumenkranz MS and Hartzer MK: Pharmacologic treatment of

proliferative vitreoretinopathy : interrelationship with the

coagulation cascade. In : Medical and surgical retina, advances,

controversies,and management. Lewis H, Ryan SJ (eds.). 11830

Westline Industrial Drive, St Louis, Missouri 63146 : Mosby Inc.,

1993 L: 172.

Blumenkranz MS and Hartzer MK: The mechanism of action of drugs

for the treatment of vitreoretinal scarring. In Ryan SJ, ed: Retina,

4th

Edition, El-Servier Inc., USA, 2006, pp. 2241-2253.

Blumenkranz MS and Hartzer MK: The mechanism of action of drugs

for the treatment of vitreoretinal scarrin. In : Retina (second

edition) (D-ROM edition). Ryan SJ, Glaser BM (eds). 11830

Westline Industrial Drive, St Louis, Missouri 63146 : Mosby Inc.,

1994; Chapter 142.

Blumenkranz MS, Hartzer MK and Iverson DA: An overview of

potential application of heparin in vitreoretinal surgery (review).

Retina 1992; 12 : 571-4.

Blumenkranz MS, Hernandez E, ophir Aand Norton EW: 5-fluororacil :

new application in complicated retinal detachment for an

established antimetabolite. Ophthalmology 1984; 91 : 122 – 30.

Blumenkranz MS, Ophir A, Claflin A, et al.: Fluorouracil for the

treatment of massive preretinal proliferation. Am J Ophthalmol

1982; 94: 458-467.

Bonnet M and Hajjar C: Clinical risk factors for proliferative

vitreoretinopathy. In Stirpe M (Ed.): Advances in vitreoretinal

surgery. Acta of the third international congress on vitreoretinal

References

153

surgery 1991, ophthalmic communications society Inc., New

York 1992; pp. 229-236.

Bonnet M, Fleury J, Guenoun S, et al.: Cryopexy in primary

rhegmatogenous retinal detachment: a risk factor for

postoperative proliferative vitreoretinopathy. Graefes Ach Clin

Exp ophthalmol 1996; 234: 739-743.

Bonnet M: Clinical factors predisposing to massive proliferative

vireoretinopathy in rhegmatogenous retinal detachment.

Ophthalmologica 1984; 188: 148-152.

Bonnet M: Macular changes and fluorescein angiographic changes after

repair of proliferative vitreoretinopathy. Retina 1994; 14 : 404-10.

Bovey EH, DeAncos E and Gonvers M : Retinotomies of 180 degrees or

more. Retina 1995; 15 : 394-8.

Brinton DA and Hilton GF: Pneumatic retinopexy and alternative retinal

attachment techniques. In : Retina (Third edition). Ryan SJ (ed.).

11830 Westline Industrial Drive, St Louis, Missouri 63146 :

Mosby Inc., 2001: 2047 – 62.

Brown GC, Brown MM, Sharma S, Busbee B, and Landy J: A cost –

utility analysis of intervention for severe proliferative

vitreoretinopathy. Am J Ophthalmol 2002; 133 : 365 – 72.

Calabresi P and Parks RE: Chemotherapy of neoplastic diseases. In

Googman AG, Oilman LS, Rail TW & Murad F (eds.): The

pharmacological basis of therapeutics, McGraw-Hill Book Co,

New York, 1985; pp 1248-1253.

References

154

Campochiaro PA and Glaser BM: Mechanisms involved in retinal

pigment epithelial cell chemotaxis. Arch Ophthalmol 1986; 104:

277-280.

Campochiaro PA and Glaser BM: Platelet-derived growth factor is

chemotactic for human retinal pigment epithelial cells. Arch

Ophthalmol 1985; 103: 576-579.

Campochiaro PA, Bryan JA, Conway BP, et al.: Intravitreal chemotactic

and mitogenic activity implications of blood retinal barrier

breakdown. Arch Ophthalmol 1986; 104: 1685-1687.

Campochiaro PA, Hackett SF, and Conway BP: Retinoic acid promotes

density-dependent growth arrest in human retinal pigment

epithelial cells. Invest Ophthalmol Vis sci 1991; 32: 65-72.

Campochiaro PA, Jerdan JA, and Glaser BM: Serum contains

chemoattractants for human retinal pigment epithelial cells. Arch

Ophthalmol 1984; 102: 1830-1833.

Campochiaro PA, Sugg R, Grotendorst G and Hjelmeland LM: Retinal

pigment epithelial cells produce PDGF-like proteins and secrete

them into their media. Exp Eye Res 1989; 49: 217-227.

Campochiaro PA: Cell dedifferentiation in proliferative

vitreoretinopathy. In Stirpe M (Ed.): Advances in vitreoretinal

surgery. Acta of the third international congress on vitreoretinal

surgery 1991, ophthalmic communications society Inc., New

York 1992; pp. 229-236.

Campochiaro PA: The pathogenesis of proliferative vitreoretinopathy. In

Ryan SJ (ed): Retina 2001 (3rd ed), Mosby Inc, pp. 2221-2227.

References

155

Casaroli Marano RP and Vilaro S: The role of fibronectin, laminin,

vitronectin and their receptors on cellular adhesion in proliferative

vitreoretinopathy. Invest Ophthalmol Vis Sci 1994; 35:

2791-2803.

Cassidy L, Barry P, Shaw C, et al: platelet derived growth factor and

fibroblastic growth factor basic levels in patients with

vitreoretinal disorders. Br J Ophthalmol 1998; 82: 181-185.

Chandler DB, Hida T, Rozakis G, Forbes VS, and Machemer R: The

lack of an effect of intraocular steroids on irradiated fibroblast in

experimental proliferative vitreoretinopathy. Graefes Arch Clin

Exp Ophthalmol 1992; 230 : 188 – 92.

Chapman C, Iverson D, Hartzer MK, Minelli E and Blumenkranz MS:

The effect of low molecular weight heparin on prliferative

vitreoretinopathy induced in the rabbit eye. Invest Ophthalmol

Vis Sci 1992; 33 (Suppl): 818.

Charles S, Katz A and Wood B: Proliferative vitreoretinopathy In:

vitreous microsurgery, 3rd ed., Lippincott Williams & Wilkins,

Philadelphia, 2002; pp. 136-152.

Charteris DG, Ayelward W, Wong D, et al: A randomized controlled

trial of combined 5-Fluorouracil and low-molecular-

weightheparin in management of established proliferative

vitreoretinopathy. Ophthalmology 2004; 111:2240-2245.

Charteris DG, Hiscott P, Grierson I and Lightman SL: Proliferative

vitreoretinopathy : lymphocytes in epiretinal membranes.

Ophthalmology 1992; 99 : 1364 – 7.

References

156

Charteris DG, Hiscott P, Robey HL, Gregor ZJ,Lightman SL and

Grierson I: Inflammatory cells in proliferative vitreoretinoatphy

subretinal membranes. Ophthalmology 1993;100 : 43 – 6.

Charteris DG: Proliferative vitreoretinopathy: pathobiology, surgical

management, and adjunctive treatment. Br J Ophthalmol 1995;

79: 953-960.

Christmas NJ, Skolik DSA, Howard MA, Saito Y, Barnstable CJ and

Ligget PE: Treatment of retinal breaks with autologous serum in

an experimental model. Ophthalmology 1995; 102 : 263 – 71.

Clearly PE and Ryan SJ: Methods of production and natural history of

experimaental posterior penetrating eye injury in the rhesus

monkey. Am J Ophthalmol 1979; 88: 220-221.

Coleman DJ, Lucas BC and Fleishmann JA: A biological tissue

adhesive for vitreoretinal surgery. Retina 1988; 8 :250 – 6.

Conner TB, Roberts AB, Sporn MB, et al: Correlation of fibrosis and

transforming growth factor-B type 2 levels in the eye. J Clin

Invest 1989; 83: 1661-1666.

Cowley M, Conway B, Campochiaro P, et al: Clinical risk factors for

proliferative vitreoretinopathy. Am J Ophthalmol 1989;

107:1147- 1151.

Dabour SA, Alkawas AA, Morshid MM, Elniel A and Hanifa HZ:

Triamcinolone – assisted pars plana vitrectomy in proliferative

diabetic retinopathy and proliferative vitreoretinopathy. Bull

Ophthalmol Soc Egypt 2004; 97 : 765 -9.

References

157

Danis RP, Ciulla TA and Pratt LM: Intravitreal triamcinolone acetonide

in exudative age – related macular degeneration. Retina 2000; 20 :

244 – 50.

Duquesene N, Bonnet M and Adeleine P. Preoperative vitreous

hemorrhage associated with rhegmatogenous retinal detachment:

a risk factor for postoperative proliferative vitreoretinopathy?.

Graefes Arch Clin Exp Ophthalmology 1996; 234: 677-82.

Elner SG, Elner VM, Diaz-Rhohena R, et al: Anterior proliferative

vitreoretinopathy: Clinicopathologic, light microscopic, and

ultrastructural findings. Ophthalmology 1988; 95: 1349-1357.

El-Toukhi EM and Adel SS: Log-term use of silicone oil in certain

cases of retinaldetachment. Bull Ophthalmol Soc Egypt 2001; 94

: 499 – 502.

Esser P, Bresgen M, Weller M, Heimann K and Wiedemann P: The

significance of vitreonectin in proliferative diabetic retinopathy.

Graefes Arch Clin Exp Opthalmol 1994; 232: 477-481.

Fathi A. Adjuvant 5-fluorouracil and low molecular weight heparin

during vitrectomy for cases of rhegmatogenous retinal detachment

with ocular hypotony. Bull Ophthalmol Soc Egypt 2004; 97:

855-858.

Fekrat S, de Juan E and Campochiaro PA: The effect of oral 13-cis-

retinoic acid on retinal detachment after surgical repair in eyes

with proliferative vitreoretinopathy. Ophthalmology 1995; 102:

412-418.

References

158

Ferrone BJ, McCuen BW II, DeJuan E and Machemer R: The efficacy

of silicone oil for complicated retinal detachment in the pediatric

population. Arch Ophthalmol 1994; 112 : 773 -7.

Fujii GY, DeJuan E and Humayun MS: Initial experience using

transconjunctival sutureless vitrectomy system for vitreoretinal

surgery. Ophthalmology 2002; 109 : 1814 -20.

Gabrielian K, Osusky R, Ryan SJ, et al: The effect of transforming

growth factor beta on interferon-gamma induced HL-DR

expression in human RPE cells. Invest Ophthalomol Vis Sci 1993;

34 (suppl): 1019.

Gad MA, El-Bendari AM and Zaky NS: Triamcinolone – assisted pars

plana vitrectomy in proliferative vitreoretinopathy. Bull

Ophthalmol Soc Egypt 2004; 97 : 771 – 3.

Gallemore RP, McCuen BW II: Silicone oil in vitreoretinal surgery. In :

Retina. Ryan SJ (ed.). 11830 Westline Industrial Drive, St Louis,

Missouri 63146 : Mosby Inc., 2001 : 2199.

Gariano RK, Assil KK and Wiley CA: Retina toxicity of the

antimetabolite 5- fluorouridine 5 –monophosphate administration

intravitreally using multivesicular liposomes. Retina 1994; 14 :

75 – 80.

Girard P, Mimoun G, Karpouzas I and Montefiore G: Clinical risk

factors for proliferative vitreoretinopathy after retinal detachment

surgery. Retina 1994; 14: 417-424.

References

159

Glaser BM and Lemor M: Pathobiology of proliferative

vitreoretinopathy. In Ryan SJ (Ed.): Retina, 2nd Edition, Mosby-

Year Book Inc., USA, 1994; pp. 2249-2264.

Glaser BM, Cardin A and Biscoe B: Proliferative vitreoretinopathy: the

mechanism of development of vitreoretinal traction.

Ophthalmology 1987; 94: 327 - 332.

Glaser BM, Vidaurri-Leal J, Michels RG, et al: Cryotherapy during

surgery for giant retinal tears and intravitreal dispersion of viable

retinal pigment epithelial cells. Ophthalmology 1993; 100: 466-

470.

Glaser BM: Surgery for proliferative vitreoretinopathy. In : Retina

(Second edition) (CD-ROM edition). Ryan SJ, Glaser Bm (eds.).

11830 Westline Industrial Drive, St Louis, Missouri 63146.

Mosby Inc., 1994; Chapter 141.

Gonzalez-Avila G, Lozano D, Manjarrez ME, et al.: Influence on

collagen metabolism of vitreous from eyes with proliferative

vitreoretinopathy. Ophthalmology 1995; 102: 1400-1405.

Greenberg PB, Martidis A and Rogers AH: Intravitreal triamcinolone

acetonide for macular edema due to central retinal vein occlusion.

Br J Ophthalmol 2002; 86 :247 -8.

Grierson I, Heathcote L, Hiscott P, et al: Hepatocyte growth

factor/scatter factor in the eye. Prog Retin Eye Res 2000, 19:

779-802.

Guerrin M, Moukadiri H, Chollet P, et al: Vasculotropin/vascular

endothelial growth factor is an autocrine growth factor for human

References

160

retinal pigment epithelial cells cultured in vitro. J Cell Physiol

1995; 64: 385-394.

Hagiwara T, Suzuki H, Kono I, et al: Regulation of fibronectin synthesis

by lnterleukin-6 in rat hepatocytes. Am J Pathol 1990; 133:39- 47.

Hartzer MK and Blumenkranz MS: Fluoropyrimidines in the treatment

of proliferative vitreoretinopathy and glaucoma. In Tso and

MOM, (ed.): Retinal diseases: biomedical foundations and

clinical management, JB Lippincott Co, Philadelphia, 1988; pp.

347-361.

Harvey AK, Roberge F and Hjelmeland LM: Chemotaxis of rat retinal

glia to growth factors found in repairing wounds. Invest

Ophthalmol Vis Sci 1987; 28: 1092-1099.

Hinton DR, He S, Jin ML, Barron E and Ryan SJ: Novel growth

factors involved in the pathogenesis of proliferative

vitreoretinopathy. Eye 2002; 16 (4): 422-428.

Hiscott P, Sheridan C, Magee RM and Grierson I: Matrix and the

retinal pigment epithelium in proliferaive retinal disease. Prog

Retin Eye Res 1999; 18 : 167 – 90.

Hiscott P, Waller HA, Grierson I, Butler MG, Scott DL, Gregor Z and

Morino I: Fibronectin synthesis in subretinal membranes of

proliferative vitreoretinopathy. Br J Ophthalmol 1992; 76 : 486 –

90.

Hiscott PS, grierson I, Trombetta CJ, et al: Retinal and epiretinal glia-

an immunohistochemical study. Br J Ophthalmol 1984; 68: 698-

707.

References

161

Hui YN, Liang HC, Cai YS and Kirchhof B: Corticosteroids and

daunomycin in the prevention of experimental proliferative

vitreoretinopathy induced by macrophages. Graefes Arch Clin

Exp Ophthalmol 1993; 231: 109 – 14.

Hutton WL, Azen SP and Blumenkranz MS for the Silicone Study

Group: The effects of silicone oil removal. Silicone Study report

6. Arch Ophthalmol. 1994; 112 : 778 – 85.

Immonen I, Siren R, Liesto K, et al: Retinoids increase urokinase type

plasminogen activator production by human retinal pigment

epithelial cells in culture. Invest Ophthalmol Vis Sci 1993; 34:

2062-2067.

Inverson DA, Dailey WA, Hartzer MK, Chapman C and Blumenkranz

MS: The effect of low molecular weight heparin on the

mitogenicity of intraocular fluid from patients with proliferative

retinopathies. Invest Ophthalmol Vis Sci 1991; 32 (suppl) : 879.

Iverson DA, Katsura H, Harzer MIC, et al: Inhibition of intraocular

fibrin formation following infusion of low molecular weight

heparin during vitrectomy. Invest Ophthalmol Vis Sci 1991b;

109: 405- 409.

Jaffe GJ, Ben-Nun J and Guo H: Flucinolone acetonide sustained drug

delivery device to treat severe uveitis. Ophthalmology 2000; 107 :

2024 – 33.

Jaffe GJ, Earnest K, Fulcher S, Lui Gm and Houston LL:

Antitransferrin receptor immunotoxin inhibits proliferating human

retinal pigment epithelial cells. Arch Ophthalmol 1990; 108:

1163-1168.

References

162

Jaffe GJ, Harrison CE, Lui GM, et al: Activin expression by cultured

human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci

1994; 35: 2924-2931.

Jarus G, Blumenkranz MS, Hernandez E and Sossi N: Clearance of

intravitreal fluorouracil : normal and aphakic vitrectiomized.

Ophthalmology 1985; 92 : 91-6.

Jerden A, Repose JS, Michel R, et al: Proliferative vitreoretinopathy

membranes. An immunohistochemical study. Ophthalmology

1989; 96: 801-810.

Johnson NF and foulds WS: Observations on the retinal pigment

epithelium and retinal macrophages in experimental retinal

detachment. Br J Ophthalmol 1977; 61: 564-572.

Johnson RN and Blankenship G: A prospective, randomized, clinical

trial of heparin therapy for postoperative intraocular fibrin.

Ophthalmology 1988; 95 : 312 – 7.

Jonas JB, Hyaler JK and Safker A : Inravitreal injection of crystalline

cortisone as adjunctive treatment of proliferative diabetic

retinopathy. Am J Ophthalmol 2001; 131 : 468 – 71.

Jonas JB, Kreissig I and Degenring R: Intraocular pressure after

intravitreal injection of triamcinolone acetonide. Br J Ophthalmol

2003; 87 : 24 – 7.

Jonas JB: Concentration of intravitreally injected triamcinolone

acetonide in intraocular silicone oil. Br J Ophthalmol 2002 a; 86 :

1450 -1.

References

163

Jonas JB: Concentration of intravitreally injected triamcinolone

acetonide in aqueous humour. Br J Ophthalmol 2002b; 86 : 1066.

Kanaski J: Clinical features of retinal detachment. In: Clinical

Ophthalmology – a systematic approach, 4th ed., Butterworth

Heimann (Elservier Ltd), 2003, pp. 365-370.

Kanaski J: Clinical features of retinal detachment. In: Clinical

Ophthalmology – a systematic approach, 6th ed., Butterworth

Heimann (Elservier Ltd), 2008, pp. 365-370.

Kauffmann DJ, Meurs JC, Mertens DA, et al: Cytokine in vitreous

humor: interleukin-6 is elevated in proliferative vitreoretinopathy.

Invest Ophthalmol Vis Sci 1994; 35: 900-906.

Khattab AM: Intraoperative visualization of the vitreous and the posterior

hyaloids using triamcinolone acetonide in vitrectomy for

proliferative vitreoretinopathy. Bull Ophthalmol Soc Egypt 2004;

97 : 733 – 7.

Khaw PT and Migdal CS: Current techniques in wound healing

modulation in glaucoma surgery. Current Opin Ophthalmol 1996;

7 : 24 – 33.

Khaw PT, Doyle JW and Sherwood MB: Prolonged localized tissue

effects from 5 – minute exposures to fluorouracil and

mitomycinC. Arch Ophthalmol 1993; 111 : 263 -7.

Khaw PT, Sherwood MB, MacKay SLD, Rossi MJ and Schultz G: Five

– minute treatment with fluorouracil, floxuridine, and mitiomycin

have long term effects on human tenon's capsule fibroblasts.arch

Ophthalmol 1992; 110 : 1150 – 4.

References

164

Khawly JA, Saloupis P, Hatchell DL, and Machemer R: Dauncorubicin

treatment in a refined experimental model of proliferative

vitreoretinopathy. Graefes Arch Clin Exp Ophthalmol. 1994; 229

: 464 -7.

Kim IK and Arroyo JG: Mechanisms in proliferative vitreoretinopathy.

Ophthalmology clinics of North America 2002; 15 : number 1.

Kivilcim M, Peyman GA and El-Dessouky ES: Retinal toxicity of

triamcinolone acetonide in silicone – filled eyes. Ophthalmic Surg

Lasers 2000; 20 : 474 – 8.

Kon CH, Occleston NL, Ayelward GW and Khaw PT: Expression of

vitreous cytokines in proliferative vitreoretinopathy: a prospective

study. Invest Ophthalmol Vis Sci 1999; 40: 705-712.

Kon CH, Occleston NL, Charteris D, et al: A prospective study of

matrix metalloproteinases in proliferative vitreoretinopathy.

Invest Ophthalmol Vis Sci 1998; 39: 1524-1529.

Kon CH, Occleston NL, Foss A, Sheridan C, Ayelward GW and Khaw

PT: Effects of single, short term exposures of human retinal

pigment epithelial cells to thiotepa or 5 – flurouracil : implications

for treatment of proliferative vitreoretinopathy. Br J Ophathalmol

1998; 82 : 554 – 60.

Kon CH, Occleston NL, Khaw PT and Aylward GW: Risk factors for

proliferative vitreoretionopathy. Br J Ophthalmol 2000; 84:

506-511.

Kosnosky W, Li TH and Palkins VA: Interleukin -1- beta changes the

expression of metallproteinases in the vitreous humor and induces

References

165

membrane formation in eyes containing preexisting retinal holes.

Invest Ophthalmol Vis Sci 1994; 35 : 4260 – 7.

Laqua H and Machemer R: Clinical pathological correlation in massive

preretinal proliferation. Am J Ophthalmol 1975; 80: 913.

Lean JS: Proliferative vitreoretinopathy. In Albert & Jakobiec (eds):

principles and practice of ophthalmology, 2nd ed, Saunders WB

comp., Philadelphia, 2000, pp 2392-2402.

Lean SJ : Proliferative vitreoretinopathy. In : Principles and practice of

ophthalmology. Albert DM, Jakobie EA (eds.). Philadlephia :

W.B. Saunders Company, A division of Harcourt Brace company,

1994 : 1110 – 21.

Lemor M, de Bustros S and Glaser BM: Low-dose colchicines inhibits

astrocytes, fibroblast, and retinal pigment epithelial cell migration

and proliferation, Arch Ophthalmol I986; 104: 1223-1225.

Leschey KH, Hackett SF, Singer JH and Campochiaro PA: Growth

factor responsiveness of human retinal pigment epithelial cells.

Invest Ophthalmol Vis Sci 1990; 31: 839-846.

Lewis H and Aaberg TM: Anterior proliferative vitreoretinopathy. Am J

Ophthalmol 1988; 105:277-284.

Lewis H, Aaberg TM and Abrams GW: Causes of failure after initial

vitreoretinal surgery for severe proliferative vitreoretinopathy.

Am J Opathalmol 1991; 111 : 8.

Lewis H: Management of severe proliferative vitreoretinopathy. In Lewis

H, Ryan SJ (eds): Medical and surgical retina, Mosby-Year Book,

St. Louis, 1994, p 119.

References

166

Lewis JM, Abrams GW and Werner JC: Management of complicated

retinal detachment. In : Ophthalmic Surgery : Principles and

Techniques. Albert DM, Robinson NL (eds). USA : Blackwell

Science Incorporated,1999 : 531 -64.

Limb GA, Earley O, Jones SE, LeRoy F, et al: Expression of mRNA

coding for TNF alpha, IL-1 beta and IL-6 by cells infiltrating

retinal membranes. Graefe Arch Clin Exp Ophthalmol 1994; 232:

646-651.

Limb GA, Little BC, Meager A, et al: Cytokines in proliferative

vitreoretinopathy. Eye 1991; 5: 686-693.

Machemer R, Aaberg TM, Freeman HM, et al: An updated

classification of retinal detachment with proliferative

vitreoretinopathy, Am J Ophthalmol 1991; 112: 159- 165.

Machemer R: Proliferative vitreoretinopathy : a personal count of its

pathogenesis and treatment. Invest Ophthalmol Vis sci 1988; 29 :

1771 – 83.

Macky TAA: Intravitreal mitomycin C-corticosteroids conjugate in

inhibition of experimental proliferative vitreoretinopathy in an

animal model. M.D. thesis in ophthalmology, Faculty of

Medicine, Cairo University, Egypt, 2001.

Malbran E, Dodds RA, Hulsbus R, et al: Retinal break type and

proliferative vitreoretinopathy in nontraumatic retinal detachment.

Graefe Arch Clin Exp Ophthalmol 1990; 228: 423-425.

Martini B: Proliferative vitreoretinal disorders : experimental model in

vivo and in vitro. Acta Ophthalmol 1992; 201 (Suppl): 1-63.

References

167

Michaelson IC and Stein R: A study in the prevention of retinal

detachment. Ann Ophthalmol 1969; 1: 49.

Michels R, Wilkinson C and Rice TA: Retinal detachment. 11830

Westline Industrial Drive, St Louis, Missouri 63146 : Mosby Inc.,

1990: 680 – 705.

Michels RG and Sjaarda RN: Macular pucker. In : Retina (second

edition) (CD-ROM edition). Ryan SJ, Glaser BM (eds.). 11830

Westline Industrial Drive, St Louis, Missouri 63146 : Mosby Inc.,

1994; Chapter 144.

Mietz H and Heimann K: Onset and recurrence of proliferative

vitreoretinopathy in various vitreoretinal diseases. Br J

Ophthalmol 1995; 79 : 874-7.

Minihan M, Tanner V and Willamson TH: Primary rhegmatogenous

retinal detachment : 20 years of change. Br J ophthalmol 2001; 85

: 546 – 8.

Morino I, Hiscott PS, Me Kechnie N, et al: Variation in epiretinal

membrane components with clinical duration of the proliferative

tissue. Br J Ophthalmol 1990; 74: 393-399.

Mruthyunjaya P and McCuen BW II: Updated indications of silicone

oil use in vitreoretinal surgery. Highlights of Ophthalmology;

2005; 33 : 9 – 13.

Parel JM and Villain F: Silicone oils physicochemical properties. In :

Retina (Second edition) (CD – Rom edition). Ryan SJ, Glaser BM

(eds.). 11830 Westline Industrial Drive, St Louis, Missouri 63146

: Mosby Inc., 1994: Chapter 132

References

168

Pastor JC: Proliferative vitreoretinopathy : an overview. Surv

Ophthalmol 1998; 43 : 3 -18.

Peczon BD, Wolfe JK, Gipson IK, et al: Characterization of membranes

removed during open-sky vitrectomy. Invest Ophthalmol Vis Sci

1983; 24: 1382-1389.

Pieramici DJ, Caponi A and Aaberg TM: Surgical management of

proliferative vitreoretinopathy. In : Retina – vitreous – macula

(first edition). Guyer DR, Yanuzzi LA, Cahng S, Shields JA and

Green WR(eds.). The Curits Center, Independence Square West,

Philadelphia, Pennsylvania 19106 : W.B. Saunders Company, A

division of Harcourt Health Science Company, 1999 : 1350 – 69.

Rachal WF and Burton TC: Changing concepts of failures after retinal

detachment surgery. Arch Ophthalmol 1979; 97:180-183.

Radwan R, Hamdy AM, and El-Marakby M: Prophylactic treatment of

retinal detachment following silicone oil removal. Bull

Ophthalmol Soc Egypt 2001; 94 : 665 -7.

Regillo C, Chang TS, Johnson MW, Kaiser PK, Scott IU, Spaide R, and

Griggs PB: Peripheral retinal abnormalities. In : American

academy of Ophthalmology, Basic and Clinical Science Course,

Section 12, Retina and Vitreous. Liesegang TJ, Skuta GL, and

Cantor LB (eds). 655 Beach Street, Box 7424, San Francisco, CA

94120-7424 : American academy of Ophthalmology, 2004: 253 –

77.

Retina Society Terminology Committee: The classification of retinal

detachment with PVR. Ophthalmology 1983; 90: 121-125.

References

169

Reuter U, Champion C and Kain HL: Transdifferentiation of human

monocytes into fibroblast-like cells in vitro. Ger J Ophthalmol

1995; 4: 182-187.

Robbins SG, Mixon RN, Wilson DJ, et al: Platelet-derived growth factor

ligands and receptors immunolocalized in proliferative retinal

diseases. Invest Ophthalmol Vis Sci 1994; 35: 3649-3663.

Ross R, Raines EW and Bowen-Pope DF: The biology of platelet

derived growth factor. [Review]. Cell 1986; 46: 155-169.

Ryan SJ: The pathophysiology of PVR in its management. Am J

Ophthalmol 1985; 100: 188-193.

Ryan SJ: Traction retinal detachment. XLIX Edward Jackson memorial

lecture. Am J Ophthalmol 1993; 115 : 1-2.

Sakamoto T, Miyazaki M, Hisatomi T, Nakamura T, Ueno T, Itaya K

and Ishibshi T: Triamcinolone – assisted pars plana vitrectomy

improves the surgical procedures and decreases the postoperative

blood – ocular barrier breakdown. Graefes Arch Clin Exp

Ophthalmol 2002;240 : 423 -9.

Schepens CL: Proliferative Vitreoretinopathy (PVR). Ophthalmology

1987; 94: 201.

Schepens CL: Vitreous changes in rhegmatogenous retinal detachment.

In Schepens CL, Hartnett ME and Hirose T (eds): Schepens’

retinal detachment and allied diseases, Butterworth-Heinemann

(Elservier group), 2000, pp 153-179.

References

170

Scott IU, Flynn HW and Azen SP: Silicone oil in the repair of pediatric

complex retinal detachments : prospective, observational,

multicenter study. Ophthalmology 1999; 106 : 1399 – 407.

Shoier A, Azab A and Rizk K: Triamcinolone acetonide – assisted pars

plana vitrectomy. Bull Ophthalmol Soc Egypt 2004; 97 : 761 -4.

Singh AK, Michels RG, Glaser BM: Scleral indentation following

cryothrapy and repeat cryotherapy enhance release of viable

retinal pigment epithelial cells. Retina 1986; 6: 176- 178.

Smith TR: Pathological findings after retina surgery. In CL Schepens

(ed): importance of the vitreous body in retina surgery with

special emphasis on reoperations, C.V. Mosby Co., St Louis,

1960.

Soliman MM and Ali KG: Mytomycin –C in the management of

proliferative vitreoretinopathy, randomized clinical study. Bull

Ophthalmol Soc Egypt 2001; 94: 653 -8.

Spee C, Hinton RT and Ryan SJ: The potential of mitomycin C in the

treatment of experimental proliferative vitreoretinopathy. Invest

Ophthalmol Vis Sic 1996: 37 : 392 -8.

Stefer U, Wiedemann P, Weber J and Heimann K : functional results

after vitrectomy with silicone oil injection. Eur J Ophthalmol

1991; 1 : 89 – 94.

Stern WH, Lewis GP and Erickson PA: Fluorouracil therapy for

proliferative vitreoretinopathy after vitrectomy. Am J Ophthalmol

1983; 96 : 33 – 42.

References

171

Stilma JS, Koster R and Zivojnovic R: Radical vitrectomy and silicone-

oil injection in the treatment of proliferative vitreoretinopathy

following retinal detachment. Doc Ophthalmol 1986; 64:

109-116.

Takagi H, Tanihara H and Yoshimura N: Gene expression of insulin-

like growth factors and insulin-like growth factor binding proteins

in cultured human retinal epithelial cells. Invest Ophthalmol Vis

Sci 1993; 34(suppl): 1019.

Tanihara H, Yoshida M, Masumoto M, et al: Identification of

transforming growth factor beta expressed in cultured retinal

pigmentepithelial cells. Invest Ophthlmol Vis Sci 1993; 34: 413-

419.

Tano Y, Sugita G, Abrams G, et al: Inhibition of intraocular

proliferations with intravitreal corticosteroids. Am J Ophthalmol

1980; 89: 131-136.

Thompson JT: Complicated forms of retinal detachment: Proliferative

vitreoretinopathy. In Ryan SJ (Ed.): Retina, 4th Edition, Mosby-

Elservier Inc., USA, 2006; pp. 2283-2309.

Tseng W, Cortez RT, Ramirez G, et al: Prevelance and risk factors for

proliferative vitreoretinopathy in eyes with rhegmatogenous

retinal detachment but no previous vitreoretinal surgery. Am J

Ophthalmol 2004; 137: 1105-1115.

Van Bockxmeer FM, Martin CE, Thompson DE, et al: Taxol for the

treatment of proliferative vitreoretinopathy. Invest Ophthalinol

Vis Sci, 1985; 26: 1140-1147.

References

172

Van Ryn-McKenna J, Cai L and Ofosu FA: Neutralization of

enoxaparine – induced bleeding by protamine sulfate. Thromb

Homeos 1990; 63 : 271 -4.

Varga J, Rosenbloom J and Jimenez SA: Transforming growth factor

beta (TGF beta) causes a persistent increase in steady-state

amounts of type I and type III collagen and fibronectin mRNAs in

normal human dermal fibroblasts. Biochem J 1987; 247: 597-604.

Verdoorn C, Renardel de Lavaiette VWR, Delma-Weizhausz J, et al:

Cellular migration, proliferation and contraction: An in vitro

approach to a clinical problem - Proliferative vitreoretinopathy.

Arch Ophthalmol 1986; 104: 1216-1219.

Verstraeten TC, Buzney SM, Macdonald SG and Neufeld AH: Retinal

pigment epithelium wound closure in vitro (pharmacologic

inhibition). Invest Ophthalmol Vis Sci 1990; 31 : 481 – 8.

Vidaurri-Leal J, Hohman R and Glaser BM: Effect of vitreous on

morphologic characteristics of retinal pigment epithelial cells: A

new approach to the study of proliferative vitreoretinopathy. Arch

Ophthalmol 1984; 102: 1220-1223.

Vinores SA, Campochiaro PA and Conway B: Ultrastructural and

electron-immunocytochemical characterization of cells in

epiretinal membranes. Invest Ophthalmol Vis Sci

(suppl)1993:983.

Vinores SA, Henderer JD, Mahlow J et al: Isoforms of plateletderived

growth factor and its receptors in epiretinal membranes:

immunolocalization to retinal pigment epithelial cells. Exp Eye

Res 1995;60: 607-619.

References

173

Vinores SA: Ultrastructural and immunocytochemical changes in retinal

pigment epithelium, retinal glia, and fibroblasts in vitreous

culture. Invest Ophthalmol Vis Sci 1990; 31 : 2529 – 45.

Walshe R, Esser P, Wiedemann P, et al: Proliferative retinal diseases:

myofibroblasts cause chronic vitreoretinal traction; Br J

Ophthalmol 1992; 76: 550-552.

Weller M, Wiedemann P and Heimann K: PVR- is it anything more than

wound healing at wrong place?. Int Ophthalmol 1990; 14 :

105-117.

White HD, Gersh BJ and Opie LH: Antithrombotic agents : platelet

inhibitors, anticoagulants, and firinolytics. In : Drugs for the heart

(fifth edition). Opie LH, Gersh BJ (eds.). The Curtis Center,

Independence Square West, Philadlephia, Pennsylvania 19106:

W.B. Saunders Company, A division of Harcourt health Science

Company, 2001: 273 – 322.

Wiedemann P, Leinung C, Hilgers RD and Heimann K: Daunomycin

and silicone oil for the treatment of proliferative

vitreoretinopathy. Graefes Arch Clin Exp Ophthalmol 1991; 229 :

150 – 5.

Wiedemann P, Soregente N, Bekhor C,Paterson R, Tran T and Ryan

SJ: Daunomycin in the treatment of experimental proliferative

vitreoretinopathy. Invest Ophthalmol Vis Sci 1985; 26 : 719 – 24.

Williams GA and Aaberg TM: Techniques of sclera buckling. In : Retina

(third edition). Ryan SJ (ed.) 11830 Westline Industrial Drive,

StLouis, Missouri 63146 : Mosby Inc., 2001: 2010 – 46.

References

174

Wilson-Holt N, Khaw P, Savage F, et al: The chemoattractant activity of

the vitreous to human scleral fibroblasts following retinal

detachment and proliferalive vitreoretinopathy. Br J Ophthalmol

1992; 76: 159-162.

Yang CM and Cousins SW: Quantitative assessment of growth

stimulating activitity of the vitreous during PVR. Invest

Ophthalmol Vis Sci 1992; 33: 2436-2442.

Yang CS, Khawley JA, Hainsworth DP, et al: An intravitreal sustained-

release triamcinolone and 5-fluorouracil codrug in the treatment

of experimental PVR. Arch Ophthalmol 1998; 116: 69-77.

Young S, Larkin and Branley M: Safety and efficacy of intravitreal

triamcinolone acetonide for cystoids macular edema in uveitis.

Clin Exp Ophthalmol 2001; 29 (Abstract): 206.

Yu HG and Chung H: Antiproliferative effect of mitomycin C on

experimental proliferative vitreoretinopathy in rabbits. Korean J

Ophthalmol 1997; 11: 98-105.